1,25(OH)2D3 723

131I-MIBG 565

18F-FDG-PET/CT 1157, 2973

5-azacytidine 1775

5-fluorouracil 1904, 2175, 2396

abiraterone 1079

abiraterone acetate 325

ABO blood group 2462

ABVD chemotherapy 2560

ACE-inhibitors 249

acetylation 2675

acquired resistance 1876

actinomycin D 2954

acute lymphoblastic leukaemia 2189

acute promyelocytic leukaemia 2819

ADAM17 2217

ADCs 1570

adenoid cystic carcinoma 1117

adherence 1172, 1513

adiponectin 872

ADIPOQ 872

ADIPOR1 872

adiposity 751

adjuvant chemotherapy 545

adoptive T-cell therapy 658

advanced gastric cancer 2079

advanced hepatocellular cancer 888

advanced melanoma 1451

advanced NSCLC 1467

aerosol delivery 1775

aflibercept 1735

AFP routine test 1657

African American 1945

age 780, 1717, 2941

ageing 219

age-period 1310

AGO2 3116

AKT 1198, 1586

alcohol 859, 1945

ALDH1 109

ALK expression 2735

ALK gene amplification 2735

ALK mutation 2735

allogeneic haematopoietic stem cell transplantation 2523

anaplastic astrocytoma 844

anaplastic lymphoma kinase 3084

androgen 1279

androgen receptor 950, 1271

angiogenesis 360, 1230, 1243, 2072, 2597, 2842

angiogenesis inhibitor 538

angiopoietin-2 2072

animal models 1579

anti-androgen 983

anti-angiogenic 1725

anticancer therapy 1056

anti-platelet therapy 1921

antisense oligonucleotide 2579

anti-tumour immunity 2167

AP-1 2248

apoptosis 164, 342, 433, 2189, 2434, 2685, 2696, 2792, 2853, 3034

aprepitant 859

AQUA 1859

aromatase 100

aromatase inhibitor 589, 1522, 2331

aromatase inhibitor resistance 1537

arsenic 235

asbestos 1965

ASNS 14

aspirin 249

attendance 597

AURKA 2445

Aurora kinases 2607

autophagy 164, 1040, 2434, 2597

Bacillus Calmette-Guérin 2106

basal-like breast carcinoma 444

baseline sum longest diameter 1476

bcg 1460

BCG immunotherapy 2106

BerEP4 2217

bevacizumab 552, 1408, 1725

bexarotene 2566

biliary adenocarcinomas 915

biliary tract cancer 2665

biochemical recurrence 641

bioconductor and R packages 1394

biological interaction 2005

biomarkers 1, 147, 379, 395, 482, 530, 641, 694, 1013, 1562, 1782, 2096, 2228, 2356, 2445, 2765, 2864

birth cohort 2467

bispecific antibodies 934

bisphosphonates 795

bladder cancer 50, 121, 1040, 1460, 1586, 2106

blood biomarkers 1657

BLT2 351

BMP 1805

BMPRIA 1805

BMSC 1198

body mass index 289, 589, 751, 1522, 1899, 2894

boiled coffee 1344

bone markers 121

bone marrow 1264

bone marrow-derived cells 360

bone metastasis 3014

borderline ovarian tumours 2774

bowel 1504

BRAF 559

BRAF mutation 2833

BRCA mutation carriers 777

BRCA1 2347, 2724

BRCA2 2724

breaking bad news 2507

breast biopsy 242

breast cancer, 42, 100, 109, 154, 257, 351, 582, 589, 597, 866, 872, 1157, 1172, 1291, 1302, 1310, 1513, 1522, 1528, 1543, 1556, 1676, 1693, 1829, 1876, 1886, 1926, 1945, 2035, 2175, 2331, 2472, 2783, 2792, 2798, 2965, 3034

breast cancer incidence 1296

breast cancer screening 242, 597

breast cancer therapy 1147

breast density 2331

breast neoplasms 1165

breast reconstruction 1181

buccodental toxicities 1750

Burkitt's lymphoma 280

C35 965

C609T 1325

c-ABL 1100

CAF 926

caffeine 1908

CAIX 1859

cancer anorexia-cachexia 1867

cancer cell migration 1829

cancer chemoprevention 1

cancer genetics 497

cancer genome analysis 827

cancer incidence 1989

cancer inflammation 739

cancer prevalence 219

cancer registration 2875

cancer stem cell 379, 950, 1252, 2619

cancer survival 42

cancer survivors 891

cancer treatment 1549

cancer-associated fibroblasts 3049

cancer-specific survival 1899

capecitabine 1408, 1744

carboplatin 538, 859, 1072, 1467

carcinogenesis 3057

cardiovascular damage 891

cardiovascular disease 60

care closer to home 1549

case–control studies 795, 1360, 2472, 2904

castration-resistant prostate cancer 325, 1079, 1711, 2579

Caucasian 1821

CCL19 1100

CCR7 1100

CD4 helper T lymphocytes 2155

CD44 variant 9 379

CD8 2705

CDH-1 994

CDH-2 994

CDK 2356

Cdk inhibition 2378

CDK6 2751

CDKN2A 2207

CEA 934

cediranib 943, 2765

celebrity 1192

cell cycle 3042

cell death biomarkers 2560

cell invasion 2810

cell membrane 195

cells of origin 1599

cellular motility 422

central tumour 184

cerebellum 844

cerebral cortex 844

cervical cancer 35, 92, 615, 1192, 1504, 2778

cervical cancer screening 1766

cetuximab 1117

changing presentation 2115

checkpoint receptors 2629

chemokine 1100, 2412

chemokines and chemokine receptors 1579, 2424

chemoprotection 2954

chemoprovention 249

chemoradiotherapy 1467

chemo-resistance 92, 965

chemotherapeutic 2131

chemotherapy 552, 891, 1117, 1243, 1414, 1428, 1549, 1904, 2175, 2340, 2554, 2954, 2980

chemotherapy response 370

Chernobyl 2286

childhood cancer 1373, 2880

childhood leukaemia 2880

children 844, 2515, 3084

chimeric antigen receptors 658

chloroquine 2597

choice 1181

cholangiocarcinoma 915, 2665, 3092

chondrosarcoma 1214

chordoma 2574

chromaffin cell tumour 565

chromogranin A 1414

chromosomal translocation 299

chromosome 16q 512

chromosome 1q 512

chromosome 6p 512

chronic 1504

chronic liver disease 1344, 1997

chronic lymphocytic leukaemia 1287

chronic myeloid leukaemia 1593

circulating microRNA 641

circulating tumour cells 1223, 2829

cisplatin 891, 915, 1904, 2096, 2548, 2980

cJun 3116

classification 1599, 1886

clear cell carcinoma 1899

clinical decision support systems 1147

clinical practice guidelines 1147

clinical trial costs 2051

clinical trials 897

clinicopathologic 1302

CLL 2434

c-met 1271

c-Met inhibitor 2619, 2803

CNS tumour risk 289

coffee 1352, 1908

coffee preparation 1344

cohort study 265, 761, 2496, 2886, 2917, 2924, 2933

cohort study timing 1310

cola 1908

collagen Type XI a 1 3049

colon cancer 138, 395, 994, 1023, 2175

colonoscopy 1437

colorectal cancer 24, 114, 131, 138, 307, 408, 667, 694, 807, 814, 934, 1004, 1013, 1338, 1352, 1408, 1420, 1437, 1618, 1636, 1725, 1744, 1782, 1839, 2207, 2445, 249, 2735, 2765

colorectal liver metastases 2396

colorectal neoplasms 387, 1243, 2005

colposcopy 1766

combination of platelet count and

neutrophil to lymphocyte ratio 401

combination study 943

combination therapy 1085

communication 836

communication skills 2507

community 1549

comorbidity 265, 2489

competing risks 1974

compliance 1513

computed tomography 1445

computer-assisted image analysis 1839

Concholepas haemocyanin 1488

concordance 2875

conjunctiva 1981

consequences of cancer treatment 2121

cooperation 1056

copy number changes 2347

cost attribution 2051

cost-effectiveness 1172, 2295, 2533

Coxsackievirus and Adenovirus

receptor 1848

CpG island methylator phenotype 1004

CRC 694

C-reactive protein 2066, 2316

CrkL 1100

CSCs 1876

CT26 tumour 2167

CTL 462

curative treatment 272, 1609

cutaneous T-cell lymphoma 2566

cyclophosphamide 1725

cyclotherapy 2954

CYP2C19 polymorphism 2803

cytokine 2072

cytology 603, 1192

cytotoxic T lymphocytes 462, 2705

dacarbazine 1451

DBC1 2675, 3042

DCIS 100

decaffeinated coffee 1908

decision making 780, 2295

deep remission 2998

deleterious BRCA1/2 mutation 1072

dendritic cells 462, 1488

Denmark 2489

dental hygiene 1367

dermatology 497

detection method 2833

development 1

diabetes mellitus type II 2924

diagnosis 694, 807, 2027

diagnostic tool 2646

diagnostic workup 242

diastolic heart function 891

DICER1 2744

diet 257, 1914, 2904

diethylstilboestrol 1079

differential expression 1848

diffuse large B-cell lymphoma 312

diffusion-weighted MRI 615, 1562

disease progression 121

disease-specific survival 1093

disparities 1302

disseminated tumour cells 1264

disulfiram 1876

DNA damage 2378, 3023

DNA damage repair 68, 3042

DNA damage response 1063

DNA methylation, 530, 1394, 3073

DNA repair proteins 68

DNA-PKcs 2654

DNp73 965

docetaxel 1085

donor lymphocyte infusion 2523

dose escalation 651

dose–response meta-analysis 1926

dovitinib 2309

doxorubicin 1206

DPEP1 694

DPYD 2347

DR5 2685

drug delivery 2142, 2368

drug resistance 2607

drug sensitivity 1063, 1599

drug therapy 60

DTH 1488

DUSP6 1063

dynamin 1 1867

E6*I mRNA 172

early breast cancer 2453

early detection 603, 1437, 2489

early detection lung cancer 530

early recurrence 1648

E-cadherin 2248

ecological study 235

EGFR 482, 1063

EGFR inhibitors 1063

EGFR mutation 1821

elderly 852, 1717, 1744

electronic patient-reported outcome

monitoring 2301

emergency 2027

emotion 836

EMT 307, 1666, 2248, 2587

endocrine therapy 589, 1537, 2959

endometrial cancer 215, 704, 756, 761, 1498, 1504, 1699, 1703, 1760, 1908, 1914

endoplasmic reticulum stress 433, 3034

EndoPredict 2959

endoscopic procedure 379

endovaginal 615

England 235, 2058

enteritis 1504

environmental exposure 2886

environmental radiation 2880

EpCAM 2217

EPHA2 2142

EpICD 2217

epidemiology 257, 289, 756, 769, 795, 1287, 1318, 2005, 2880

epidermal growth factor 207

epidermal growth factor receptor 1821, 2155

epidermal growth factor-like domain 7 1243

epigenetic 2266

epigenetic alteration 807

epigenetics 408

epigenome 1775

epithelial ovarian cancer 1685

epithelial-to-mesenchymal transition 184, 307

ERCC1 2096

erlotinib 1786, 2803

E-selectin 3014

ESFT 195

esophageal cancer 1367

estradiol 1522

ethinylestradiol 1537

ethnicity 780

ETV1 1625

European Organisation for Research

and Treatment of Cancer

QLQ-C30 852

evaluation 2987

evening appointment 597

everolimus 1482, 1755

evolutionary game theory 1056

Ewing sarcoma 2696, 658

ex vivo 1223

excess treatment costs 2051

exemestane 2453

exogenous hormones 1954

extended therapy 589

external gamma radiation 1989

extracellular ATP 1666

extracellular matrix proteins 3049

EZN-4176 2579

fallopian tube cancer 603

false-positive referral 2044

family history 788

female 859

fertility 615, 2778

FFPE 2404

FGFR1 2248

FGFR3 50

FHL2 114

fibrinogen 1123

filtered coffee 1344

fine-needle biopsies 2646

first treatment evaluation 2998

fish 756

FKBP51 signalling 2189

flavonoids 1914

fluorodeoxyglucose positron emission

tomography-computed

tomography 1445

focal adhesion turnover 2810

folate 2175

FOLFOX/XELOX 2765

follicular lymphoma 1287

follow-up 29, 312, 623, 866, 1766

food 2904

four-and–a-half LIM domains protein 2 114

FOXO3 protein 387

FOXO3a 1198

fragile sites 2347

FSH 1522

FTO 872

fucosyltransferase 3014

fulvestrant resistance 2751

functional characterisation 2228

Fyn 1214

gallbladder cancer 915

GalNAc-T3 472

GalNAc-T6 472

gamma-glutamyltransferase 610

gamma-glutamyltranspeptidase

(GGT) 610

gastric cancer 379, 2199, 2217, 2619

gastrointestinal cancer 2829

gastrointestinal stromal tumour 1403, 2309, 2574

gefinitib 1786

gemcitabine 915, 2566

gemcitabine resistance 502

gemcitabine-refractory 920

gene amplification 299

gene expression 1599, 2228, 2286

gene fusion 1051

gene methylation 1775

genetic 714

genetic testing 777

genomics 1636

GEP-based score 676

geriatric oncology 272

germ cell and embryonal 60

germ cell tumours 2744

g-glutamyl hydrolase 2175

GIST 1403, 1625

Glasgow Prognostic Score 24

Gleason grade 2115

glioblastoma 164, 433, 844, 2853

GLTSCR2 2199

glucose-regulated proteins 370

glycolysis 976

GNA11 493

GNAQ 493

goserelin 582

GPER 2751

graft-vs-tumour effect 2523

granulosa cell tumour of the ovary 29

Great Britain 1965

growth arrest 2587

growth factors 1056

GRP78 433

g-secretase inhibitor 667

GSTM3 3105

guideline adherence 1147

gynaecological cancer symptoms 882

gynaecological oncology surgery 623

H. pylori eradication 2323

haematological malignancy 565, 2886

haemoptysis 1609

hair colour 747

Hashimoto's thyroiditis 2496

HBV infection 2917

HCC-ART score 1657

HCV infection 2917

HDACi 676

head and neck cancer 172, 1093, 2096, 2629

head and neck squamous cell

carcinoma 482, 1859, 2155, 2973, 3049

health inequalities 780

health status disparities 1318

health-care rationing 888

health-related quality of life 852

heat-shock proteins 370

heat-shock transcription factor-1 1648

help-seeking 882

hematopoietic stem cell

transplantation 2515

hepatic resection 1428

hepatitis 2924

hepatitis B 573

hepatitis C virus 2481

hepatocellular carcinoma 14, 83, 573, 1031, 1198, 1648, 1657, 1904, 2072, 2481, 2654

HER1/EGFR 2453

HER2 1157, 2453, 2829, 2453

hereditary breast cancer 154, 2724

HES1 1023

heterogeneity 1056

HEY1 1023

Hif1 2131

Hif1a 83

high-grade glioma 844

histone modifications 299, 994, 3073

HIV 1974, 1981

HNSCC 2636

Hodgkin's lymphoma 280, 2560

homing 3014

homologous recombination 3042

hormonal therapy 1513

hormone refractory 1711

hormone replacement therapy 1895, 1954

hot flashes 1291

HOTAIR 2266

HPV 172, 2096

HPV genotyping 2941

HPV infection 184

HPV prevalence 2941

HPV screening 2941

HPV types 2941

HSF1 2654

hSWI/SNF 2751

human cytolytic fusion proteins 1570

human papillomavirus 1766, 1981, 2941

human tumour xenografts 1562

HUNT 1310

hyaluronidase 1556

hydrophilic 318

hypersensitivity 1072

hypertension 2924

hypothyroidism 215

hypoxia 50, 1795, 1859, 2597

hypoxia-regulated miRNAs 50

hysterectomy 1760

IAPs 2368

IFN-b 1198

IFN-g 76

IGF1R/mTOR signalling pathway 2189

ILK 2842

image analysis 1618

imatinib 1403, 1408, 1725, 2309, 2574

immune cells 1839, 2207

immune infiltration 1031, 1618

immune phenotype 76

immunocytochemistry 1264

immunocytokines 1206

immunohistochemistry 1252, 1618, 1839, 1886, 2665, 2833

immunomagnetic selection 1264

immunosuppression 280, 1974

immunotherapy 1570, 2155, 2412

immunotoxins 1570

incidence 219, 2467

indolent ductal carcinoma in situ 2035

induced gene 100

inequalities 1181

inflammation 147, 395, 416, 1839, 2316, 2665

inflammation-based prognostic

system 401

inflammatory breast cancer 318

ING4 2842

inguinofemoral lymphadenectomy 2533

injury 1504

insulin resistance 2792

intensity hypothesis 1965

interaction 265

interferon 2481

interleukin-6 131

interlukin-2 2412

internal plutonium exposure 1989

intra-arterial 2980

invasion 1137, 1666, 3049

invasive front 184

iodine-131 2286

ionising radiation 2286

ipilimumab 8

IRF-1 76

irinotecan 1420, 1428, 2619, 3067

Irinotecan sucrosofate 920

irradiation 1829

Ishak stage 573

ITGA6 2636

Jade Goody 1192

Jewish 777

JWA 2842

Kashmir 1367

Ki67 1859, 2792

KIT 559, 1625

Koehne's risk classification 1428

KRAS 3057, 3067

KSR1 2675

lactate dehydrogenase 2066

LAMC2 2636

laryngeal cancer 172

L-asparaginase 14

late relapse 2959

LC-MS/MS 1867

lead time 2014

lenvatinib 538

letrozole 100

leukaemia 2886

lifetime drinking 1945

LINE-1 408

LINE-1 elements 3073

lipophilic 318

liposome 920

liver cancer 1344, 1997

liver metastasis 2445

liver neoplasm 1904

liver-limited disease 1428

local inflammatory response 131

localised prostate cancer 272

locally advanced 2554

locoregional recurrence 866

logistic regression 2880

long non-coding RNAs 2266

long-term 545

long-term survival 1428

low-dose aspirin 1921

LPCAT1 1279

lung adenocarcinoma 1100, 1609

lung cancer 538, 1467, 1699, 1775, 1954, 2066, 2301, 2404

lung cancer epidemiology 1974

lung cancer prognosis 1974

lung cancer screening 530

lung neoplasm 2058

lung progression 1579

lymph node density 2087

lymph node metastasis 1685, 1693

lymph node ratio 1165

lymphocytes subsets 1676

lymphoma 1556

lysine-specific demethylase 1 994

lysyl oxidase 2237

magnetic resonance imaging 1528, 2987

major histocompatibility complex

class II 2155

malignancy 2714

malignant clone expansion 2819

malignant melanoma 3116

malignant mesothelioma 1813

malnutrition 1093

mammaglobin B (SCGB2A1) 462

mammary gland 1829

mammographic screening 2467

mammography 597, 2331

MAPK 493

markers 714

Markov model 2035

Maspin 1636

matrix degradation 422

matrix metalloproteinase (MMP) 731

maxillary sinus 2980

Mayak radiation workers 1989

MC1R 747

MCF-7 breast cancer cells 2751

MCG 101 1867

MDM2 2199

MDR 2356

MDR1 drug resistance 2131

mean survival 1735

meat 756

meat mutagens 756

median survival 1735

Mediterranean diet 1360

meetings 2295

MEK 1562

melanocortin-4 receptor 1867

melanoma 8, 265, 433, 444, 497, 2412, 2833, 2842

melatonin 83

memory T cells 1488

meningioma 289, 1051

menopause 1291, 1945

mesothelioma 552

mesothelioma latency 1965

MET 1271, 2248

meta-analysis 2894

metabolic response 1157

metabolic syndrome 60

metabolism 976

metastasis 994, 1109, 1137, 1230, 1543, 1636, 1666, 1685, 1829, 2266, 2554, 2636, 2714, 2810, 307, 3092

metastatic breast cancer 1537

metastatic colorectal cancer 1428, 3067

metastatic phenotype 1618

metastatic renal cell carcinoma (mRCC) 2998

metastatic/advanced disease 909

metformin 2792

methionine 1926

methotrexate 2175

methylxanthines 1908

metronomic 1725

metronomic cyclophosphamide 957, 2574

microarray 207, 1394, 1599

microenvironment 1648

microRNA 502, 641, 714, 1243, 1271, 2724, 2744, 2853, 3092

microRNA profiling 2724

microRNAs 452, 2646

microsatellite instability 1004, 3057

migration 207

miR-100 50

miR-106a 452

miR-106b 2323

miR-125b 2853

miR-17 1625

miR-20a 1625

miR-21 2323

miR-221 2714

miR-222 1625, 2714

miR-29s 2636

miR-302c 723

miR-320c 502

miR-34c 1271

miR-375 92

miR-520c 723

miR-591 452

miR-92a 731

miRNA 2189

miRNA 2404, 3116

modelling 2035

moderately emetogenic chemotherapy 859

module validation study 852

molecular diagnosis and prognosis 2404

molecular diagnostic technique 1693

molecular diagnostics 530

monitoring 1528

monocarboxylate transporter-4 1648

mortality 2467

mouse models 658

MRI 2965

MRP-1 195

mTOR 164, 686, 1786

mTOR inhibitors 1755

mTORC1 2389

mTORC2 2389

mucosa-associated lymphoid tissue 1 207

mucositis 2515

multi-disciplinary team 1445, 2295

multidrug resistance 351

multikinase inhibitor 888

multilevel analysis 1437

multiple myeloma 676

multiple treatment lines 2301

multitumour tissue microarray 1848

mutation 1703

mutation analysis 1593

mycosis fungoides 2566

myeloablative conditioning 2523

myeloid leukaemia 1895

nab-paclitaxel 926

nasopharyngeal carcinoma 788, 2462, 2987

National Health Insurance Research

Database 2933

natural compounds 2587

neoadjuvant chemotherapy 1157, 1528, 2792, 2798, 2965

neoplasia 1192

neoplasm metastasis 387

neoplasms 60, 1318

nephroureterectomy 1130

Netherlands 2467

nested case–control study 1997

neural stem markers 444

neuroblastoma 433

neuroendocrine tumour 565, 1414

neutrophil-lymphocyte ratio 24, 401, 1755, 1813

next-generation sequencing 827

NF-kB 76

NGR-hTNF 360

NKG2D ligands 723

nomogram 1109, 1130, 1498, 2774

non-Hodgkin's lymphoma 280, 312

non-invasive imaging 1562

non-melanoma skin cancer 235, 1287

non-persistence 1513

non-small cell lung cancer 530, 545, 1223, 1252, 1264, 1476, 1821, 1974, 2803

Notch 667

notch signalling 1023

NQO1 1325

NRAS 559

nuclear hormone receptor 299

nuclear power 2880

nuclear translocation 76

nulliparity 769

nursing 2121, 3005

nut consumption 2911

nutlin-3 2685, 2954

nutrient 2904

obesity 589, 751, 814

obstructive uropathy 2933

occupational exposure 1965

oesophageal adenocarcinoma 370

oesophageal cancer 1445, 2894

oesophageal squamous cell carcinoma 1109, 2266

oestrogen 100

oestrogen receptor 2453

oncofetal fibronectin 1206

oncogenic mutation 493

ophthalmology 497

oral cancer 207

oral cavity 2087

oral contraceptives 1895, 1954

oral dysplasia 2864

oral health 1367

oral squamous cell carcinoma 1859

oropharyngeal cancer 2904

OSNA 1693

OSSN 1981

osteoporosis/drug therapy 795

osteosarcoma 1579, 2142, 2228, 2607

outreach 1549

ovarian cancer 452, 462, 603, 610, 751, 769, 965, 1072, 1786, 2368, 2744

overall survival 121, 318, 1093, 1760

overdiagnosis 2014

oxaliplatin 1408, 1420, 2396

oxidation 983

p16INK4a 172, 2207

p21 2378

P2Y2 receptor 1666

p38MAPK 2853

p53 2434, 2675, 2685, 2696, 2853, 2954

paclitaxel 92, 538, 1482, 1876

paclitaxel resistance 351, 452

PALB2 154

palliative chemotherapy 1467, 2301

pancreatic cancer 416, 502, 739, 920, 1360, 1795, 1805, 2424, 2911, 2917, 2924

pancreatic intraepithelial neoplasia

(PanIN) 2424

parent 836

parity 769

pathological complete response 1157, 2705

pathways 2027

patient experience 780

patient survival 2665

patient-reported 623

patients preferences 633

PAX3/7-FOXO1 3084

pazopanib 1040, 1414

PCNA 2378

PDA 926

pelvic floor 3005

penis cancer 2554

pentraxin family 739

pepsinogen 2323

perimenopausal 582

peritoneum 1685

pERK 915

persin 3034

personalised diagnostics 704

personalised medicine 866

PET–CT 312

P-glycoprotein 351

Pgp 195

pharmacodynamic 897, 1782

pharmacokinetics 1744

pharmacology 2356

phase I clinical trial 897, 1043, 1085, 2560, 2579, 2803

phase II 897

phase III randomised controlled trial

651

phase-1b 1482

phosphoethanolamine 2819

phosphorylated Pyk2 1252

photodynamic therapy 976, 2167

photoreceptor 512

physical activity 761, 814

physical therapy 3005

PI3K 1085

PIAS4 1795

PICT1 2199

pigmentation traits 747

PIK3CA 1085

plasma 3067

plasma DNA 807

platelet-activating factor 1279

platinum-based chemotherapy 1223,

2378, 2548

PLCO 1352

plitidepsin 1451

pN1 1165

Polycomb 299, 1699

polymorphism 957, 1325, 2331 3105

pooled analysis 1954

population-based 272

positron-emission tomography 1414

post-mastectomy radiation therapy 1165

postmenopausal women 761

postoperative complications 623, 1310, 2894

post-treatment surveillance 2973

prediction 3067

prediction of drug sensitivity 676

predictive biomarker 14

predictive biomarkers 1243

predictive factor 1165

premenopausal 582

preoperative chemotherapy 1693

pretargeting 934

pre-therapeutic 1223

PRIMA-1Met/APR-246 2696

primary care trusts 888

primary systemic therapy 2705

Pro187Ser 1325

proanthocyanidins 1914

processing 1394

proctopathy 1504

prognosis 14, 147, 1004, 1013, 1031, 1123, 1137, 1252, 1264, 1338, 1609, 1685, 1782, 1839, 215, 2259, 2266, 2316, 2340, 2445, 2462, 2714, 2778, 2842, 3067, 3105, 395, 416, 472, 573, 610, 788, 2066, 2864

prognostic factors 29, 866, 1165, 1428, 1813, 2714, 3057

prognostic marker 138, 2654

prognostic model 332

prognostic/predictive marker 2765

progression 1460

progression-free survival 318, 1760

proliferation 2189, 2207

propensity score 1904

prospective cohort study 751, 1344, 1352, 2911

prostate cancer 641, 651, 747, 950, 957,

983, 1271, 1279, 1666, 1711, 2115, 2121, 2131, 3014, 3023

prostate cancer treatment 633

prostate cancer vaccine 1488

pro-survival signaling 2587

proteomics 704, 1636, 2142, 2378

PRRX1 307

PSA 1488

PSEN2 2217

psychological distress 1373

Pt-(GpG) DNA adducts 1223

PTEN 1586

PTEN expression 1703

public goods 1056

Pyk2 1252

pyrosequencing 2833

QALYs 1172

Q-TWiST 8

qualitative 1181

quality of care 1147

quality of life 1543, 2301, 2783, 3005

questionnaire 1543

race 1945

radiation 1504, 2340, 3023

radiation associated breast

angiosarcoma 2340

radical prostatectomy 272

radical trachelectomy 2778

radionuclide imaging 934

radionuclide therapy 934

radiotherapy 272, 651, 1093, 1117, 2980, 3005

radon 235

rapamycin 1586, 2597

rare tumour 3057

re-attendance 2044

rectal cancer 3073

recurrence 379, 1338, 1460, 1498, 1513, 2973, 3073

red hair 747

reduced intensity conditioning 2523

referral 242, 2027

registry 1403

regulatory T cells 2167, 2629

relapse 29

relapse risk 2774

renal cancer 332, 686

renal cell carcinoma 121, 147, 472, 714, 1123, 1137, 1230, 1750, 1755, 1899, 2389, 3105

renal cell tumours 2646

repeated testing 2833

reporting practices 897

representative cell line 1599

research costs 2051

resection 573

residents 2507

resistance 1230, 1593

response 2798

response evaluation criteria in solid

tumours 1476

response monitoring 2965

retina 512

retinoblastoma 512

reverse phase protein array (RPPA) 370

reversine 2810

Reversion-inducing Cysteine-rich

protein with Kazal motifs

(RECK) 731

rhabdomyosarcoma 2523

ribosomal s6 protein kinase 4 1137

risk 1914, 3105

risk assessment 1460

risk factor 769, 1360, 2904

risk prediction model 1296

risk profiles 2115

risk score 2481

rituximab 1556

RMS 3084

RNAi 3116

RNA-Seq 1051

RNAseq 1599

RO4929097 943

Ron antibody 482

Ron receptor 482

route 2027

RPL11 2199

rs1800566 1325

RTK 3084

S-1 545, 1420

S-1 plus cisplatin therapy 2079

safety 1408

salivary adenoid cystic carcinoma 444

sarcoma 1206, 1717

sarcopenia 325

SCCC 1981

schwannoma 289

screening 35, 249, 603, 1192, 2014

screening history 35

screening mammography 2044

second malignancies 1287

second-line 920

SEER program 1318

self-reporting 2875

senescence 2207

sensitivity to apoptosis 1063

sentinel lymph node biopsy 2533, 2783

serous carcinoma 603

SerpinB5 1636

serum 641

serum vitamin D 1997

service provision 1181

sex cord-stromal tumours 2744

shear-wave ultrasound 2798

shiftwork 2472

shRNA 3116

sialyl-6-T 2106

sialyl-Tn 2106

side population 2619

sigma-2 receptor 2368

signal pathways 714

signal transducer and activator of

transcription 3 (STAT3) 731

signature genes 1599

SILAC 2675

sinonasal melanoma 559

sinusoidal obstruction syndrome 2396

siRNA 3116

sirolimus 1786

skeletal-related events 121

Smac 2368

SMAD4 1805

small intestine adenocarcinoma 3057

small-cell lung cancer 1482

SMARCC1 502

smoking 814, 2489

Snail 2248

socioeconomic factors 2489

soft tissue sarcoma 909, 2316

sorafenib 342, 888, 915, 2072

SOX10 444

SOX9 1023

spindle cell 2259

splicing 195

squamous 2087

squamous cell carcinoma 1981, 2259

squamous cell lung cancer subtypes 1599

Src 1214

SS18-SSX 1 2279

SS18-SSX 2 2279

staging system 2987

standardized incidence ratios 229

STAT1 138

STAT3 83, 138

statin 249, 318

stem cells 950, 2587, 3023

stratification 1886

stroma 926

strontium 2886

STS 1717

subcutaneous administration 1556

sunitinib 332, 1040, 1403, 1750, 2309

supplements 257

supportive care 888, 2121

surgery 42, 1109, 2340

surveillance imaging 312

surveillance PET 312

surveys 780

survival 147, 195, 215, 219, 257, 493, 565, 788, 814, 1302, 1338, 1476, 1676, 1703, 1805, 2005, 2027, 2058, 2066, 2087, 2462, 2548, 2735, 2894, 2973, 3073

survival after surgery 401

survival analysis 29, 2279

survivorship 1373, 2121

symptom survey 882

synergistic antitumour 342

synergy 2005

synovial sarcoma 2279

systemic analysis 704

systemic inflammatory response 131,

401

Taiwan 2933

tamoxifen 582, 1172, 2453, 3034

targeted therapy 332, 909, 1755, 2142, 2607

taxane 2131

T-cell lymphoma 280

tea 1352, 1908

telomerase 497

temsirolimus 1711, 2389

tenovin-6 2434

testicular 2744

testicular cancer 891

testicular tumours 68

testosterone 950

tetrandrine 342, 2864

TFII-I 3042

TGF b 2167

therapeutic target 1579

therapy 2714

thoracic surgery 2058

thrombocytosis 401

thyroid cancer 2286

thyroid gland 215

thyroid-stimulating hormone 215

tissue microarray 138, 387

tivantinib 2803

TKI 1040

TNF signalling 422

TNF-a 76

TNFAIP8 1685

toluidine sulphonamide 2131

tooth loss 1367

torisel 1711

TP53 1214, 2199

trabectedin 1717

trachelectomy 615

TRAIL 2685

training 2507

transcription factor 3042

transforming growth factor-b 207

transplantation 280

trastuzumab 1556

treatment cost savings 2051

treatment costs 2051

treatment sequencing 1079

trends 242, 1318

triadic consultation 2507

trials 1

triple-negative breast cancer 2347

truncation mutation 299

TSU-68 2079

tubal ligation 1291

tuberclosis infections 229

tuberculosis 2933

tumorigenicity 2228

tumour angiogenesis 2237

tumour antigens 2155

tumour differentiation 2424

tumour dimensions 1476

tumour endothelial cells 2237

tumour glycosylation 2106

tumour invasion 422

tumour microenvironment 2412

tumour morphology 154

tumour necrosis 131

tumour progression 3049

tumour response 1528, 2356

tumour shrinkage 2998

tumour size 1476, 2035

tumour suppressor 2636

tumour suppressor gene 807

tumour targeting 360

tumour-associated antigen 1031

tumourigenesis 3092

tumour-infiltrating lymphocyte 1013, 2629, 2705

tumour-infiltrating macrophage 1013

tumour-necrosis factor 1206

tumour-stage characteristics 1921

two-dimensional electrophoresis 1867

tyrosine kinase inhibitor 538, 686, 1230, 1403, 1593, 1755, 1821

UGT 950

UK 2875

UKGOSOC 623

ulcerative colitis 694

unknown primary 1318

uPAR 2714

upper urinary tract 1130

urinary irritative symptoms 3005

urinary tract cancer 2933

urokinase-type plasminogen activator

system 2714

urologists 633

urothelial carcinoma 1130, 2548

uterine cervical neoplasms 2489

uveal melanoma 493

validation 1123, 1130, 1296, 1460, 1498, 2774

vascular invasion 472, 1609

vascular targeting 360, 1206

VEGF 83, 957

VEGF-targeted therapy 2998

VELOUR 1735

vinflunine 2548

vinorelbin 1467

viral oncogenesis 172

vitamin B12 1926

vitamin B6 1926

vitamin C 257

vitamin D 747

vulva 2259

vulvar cancer 184, 2533

VX-680 2607

waiting times 42

weekend appointments 597

weight gain 872, 1310

weight loss 1093

whole-body magnetic resonance

imaging 658

whole-genome microarray 2286

Wnt 667

wortmannin 1586

XPF 2096

young women 35, 109, 1302

ZD6474 164

ZM447439 2607

ZSTK474 1786